{
  "id": 5332875,
  "title": "STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more",
  "url": "https://urgent.news/2026/09/03/stat-were-reading-about-an-ultragenyx-failure-revmed-for-lung-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T13:18:08.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/09/03/pharmalittle-ultrangenyx-gene-therapy-failure-rev-med-lung-cancer/"
  },
  "original_language": "en",
  "account": "Today, we bring you a trio of updates from the world of medicine and research. First, we have troubling news from Ultragenyx regarding an experimental gene therapy for Angelman syndrome. The Phase 3 study showed no benefit compared to a placebo, despite early promising results. This failure is a significant setback for the company and its patients. Ultragenyx is now looking to cut costs as a result.\n\nOn a more positive note, a game-changing drug for advanced pancreatic cancer has once again shown promise. Just a week after receiving U.S. approval, the same therapy is now being tested against the world's biggest cancer killer - lung cancer. In a small trial of non-small cell lung cancer patients with specific RAS family protein mutations, the drug called Rasonque from RevMed shrank tumors in over 30% of participants. While a larger study is still underway, these early results are encouraging.\n\nAs we continue to follow these developments, stay tuned for more updates from the frontlines of medical progress.",
  "summary": "The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter",
  "key_points": [
    "Ultragenyx's gene therapy for Angelman syndrome failed Phase 3 study",
    "RevMed's Rasonque shows 30% tumor reduction in lung cancer trial",
    "Drug approved for pancreatic cancer now tested for lung cancer"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}